Swiss

Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma

Retrieved on: 
Friday, September 1, 2023
Swiss Federal Institute of Technology, Swiss, Braunschweig, Scripps Research, Therapy, Biopharmaceutical, Ibete, Anticalin, CSO, Institute of technology, Biotechnology, Hansa, United States Air Force Scientific Advisory Board, Research, Science, Boehringer Ingelheim, Natural science, Executive Committee, Immunoglobulin G, Walter, Biology, Ghassan Hitto, Research fellow, Industrial Affairs Committee (Iceland), Technical University of Braunschweig, Swiss Federal Institute of Aquatic Science and Technology, Fine chemical, Sanofi

LUND, Sweden, Sept. 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Dr. Hitto Kaufmann has been appointed as Hansa's Chief Scientific Officer (CSO) effective 1 December 2023.

Key Points: 
  • LUND, Sweden, Sept. 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Dr. Hitto Kaufmann has been appointed as Hansa's Chief Scientific Officer (CSO) effective 1 December 2023.
  • Dr. Kaufmann joins Hansa from Pieris Pharmaceuticals where he has served as Chief Scientific Officer since 2019.
  • Søren Tulstrup, President and CEO, Hansa Biopharma said, "We are thrilled to welcome Hitto to Hansa at this pivotal time.
  • Dr. Hitto Kaufmann has served as Chief Scientific Officer at Pieris Pharmaceuticals since 2019.

Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma

Retrieved on: 
Friday, September 1, 2023
Swiss Federal Institute of Technology, Swiss, Braunschweig, Scripps Research, Therapy, Biopharmaceutical, Ibete, Anticalin, CSO, Institute of technology, Biotechnology, Hansa, United States Air Force Scientific Advisory Board, Research, Science, Boehringer Ingelheim, Natural science, Executive Committee, Immunoglobulin G, Walter, Biology, Ghassan Hitto, Research fellow, Industrial Affairs Committee (Iceland), Technical University of Braunschweig, Swiss Federal Institute of Aquatic Science and Technology, Fine chemical, Sanofi

LUND, Sweden, Sept. 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Dr. Hitto Kaufmann has been appointed as Hansa's Chief Scientific Officer (CSO) effective 1 December 2023.

Key Points: 
  • LUND, Sweden, Sept. 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Dr. Hitto Kaufmann has been appointed as Hansa's Chief Scientific Officer (CSO) effective 1 December 2023.
  • Dr. Kaufmann joins Hansa from Pieris Pharmaceuticals where he has served as Chief Scientific Officer since 2019.
  • Søren Tulstrup, President and CEO, Hansa Biopharma said, "We are thrilled to welcome Hitto to Hansa at this pivotal time.
  • Dr. Hitto Kaufmann has served as Chief Scientific Officer at Pieris Pharmaceuticals since 2019.

Bruker Enables Advanced Life-Science and Green-Tech Research in the UK

Retrieved on: 
Monday, July 10, 2023
Technology, Engineering, Other Energy, Manufacturing, Nuclear, Energy, Other Science, Environment, Research, Sustainability, Software, Science, Green Technology, Data Management, Hertz, Swiss, Partnership, University, ETHZ, Federal Institute of Science and Technology, Bio, NMR, Deep learning, WMG, University of Warwick, Lipid, Intelligence, University of South Carolina, Multimedia, Cloud computing, Protein, Dicarboxylic acid, Data analysis, Acquisition, Investment, Biofuel, Magnet, Carbohydrate, Drug discovery, United Kingdom, Merck, Helium, AI, Conference, Medical imaging, Medical device, Bruker

At the EUROMAR Conference 2023 in Scotland, Bruker showcases the latest innovations in magnetic resonance technology for life science and materials science research.

Key Points: 
  • At the EUROMAR Conference 2023 in Scotland, Bruker showcases the latest innovations in magnetic resonance technology for life science and materials science research.
  • Bruker is committed to providing solutions for reducing helium consumption, such as the new HelioSmart-R system for collecting helium gas boil-off from magnets.
  • Dr. Falko Busse, President of the Bruker BioSpin Group, concluded: “We are pleased to support the advancements in scientific and drug discovery research in the United Kingdom with Bruker innovations.
  • We view the UK investments in advanced life and materials science research infrastructure as pivotal for the advancement of science, drug discovery and a green-tech economy, and we are proud to support these visionary endeavors.

Shenzhen’s Guangming Science City Gathers International Scientists to Exchange Research Achievements and Academic Development Trends

Retrieved on: 
Monday, July 3, 2023
Technology, Research, Other Technology, Other Education, Continuing, University, Other Science, Science, Education, Swiss, Swiss Federal Institute of Technology, Tsinghua-Berkeley Shenzhen Institute, Culture, Sun, Multimedia, Seminar, YSF, Practice, Bright, International Seminar of Young Tibetologists, Advanced technology, The Seminar, Human, School, Material, City, Technical University of Crete, Federal Institute of Science and Technology, Southern University of Science and Technology, Management, Guangming District

Dozens of scientists from all over the world participated in the International Seminar on New Materials either offline or online on June 30, which was organized by Guangming Science City in Guangming District, Shenzhen Municipality, South China.

Key Points: 
  • Dozens of scientists from all over the world participated in the International Seminar on New Materials either offline or online on June 30, which was organized by Guangming Science City in Guangming District, Shenzhen Municipality, South China.
  • Shenzhen is one of the youngest cities in China, where Guangming Science City is synonymous with youth, vitality, openness, and diversity.
  • With a focus on the fields of life science, information, and materials, Guangming Science City is rolling forward the building of a series carrier of major science and technology innovation.
  • Guangming Science City is developing into a hub for scientific and industrial innovation with global influence.

ONWARD Announces First-in-Human Use of ARC-IM™ Lead to Restore Movement and Function after Spinal Cord Injury

Retrieved on: 
Monday, May 15, 2023
Blood pressure, Lead, Swiss, IPG, University, University of Calgary, Lausanne, Spinal cord, ARC, Quality of life, Research, CHUV, Movement, Euronext, Patient, EPFL, SCI, FDA, Swiss Federal Institute of Aquatic Science and Technology, Pharmaceutical industry, Medical device, Nature, MD

EINDHOVEN, the Netherlands, May 15, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced the successful first-in-human use of its investigational ARC-IM Lead.

Key Points: 
  • EINDHOVEN, the Netherlands, May 15, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced the successful first-in-human use of its investigational ARC-IM Lead.
  • The ARC-IM Lead delivers targeted electrical pulses to the spinal cord and is a key component of the ONWARD ARC-IM system, an innovative platform engineered to deliver ARC Therapy to address multiple indications.
  • The ARC-IM Lead is designed to be used with the ARC-IM neurostimulator (IPG) and is purpose-built for placement along the spinal cord to stimulate the dorsal roots, with specific parameters designed for each anatomical location.
  • “The purpose-designed ARC-IM Lead will unlock our ability to optimally deliver ARC Therapy to address many of the challenges faced by people with spinal cord injury,” said Dave Marver, CEO of ONWARD.

Nyxoah Appoints Christoph Eigenmann as Chief Commercial Officer

Retrieved on: 
Wednesday, May 10, 2023
Swiss Federal Institute of Technology, Mont-Saint-Guibert, CET, Senior, Obstructive sleep apnea, Marketing, Sales & Marketing Executives International, Biotechnology, Christoph, Christoph Eigenmann, Euronext, Chemical engineering, Patient, Growth, Johnson & Johnson, Neuro, Swiss Federal Institute of Aquatic Science and Technology, Pharmaceutical industry, Swiss

Mont-Saint-Guibert, Belgium – May 10, 2023, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Christoph Eigenmann as Chief Commercial Officer.

Key Points: 
  • Mont-Saint-Guibert, Belgium – May 10, 2023, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Christoph Eigenmann as Chief Commercial Officer.
  • Christoph will oversee commercial activities globally, be responsible for sales and marketing in existing markets, and new market development.
  • Christoph brings a wealth of experience in medical technologies to Nyxoah.
  • Christoph's years of experience in commercializing medical devices globally will be invaluable as Nyxoah prepares to enter the U.S. market and expands its commercial presence internationally,” commented Olivier Taelman, Nyxoah Chief Executive Officer.

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees 

Retrieved on: 
Wednesday, May 10, 2023
Molecular biology, The Elements of Style, Journal of Thoracic Oncology, Internet Technical Committee, Law, Lung cancer, Oncology, Article, Doctor of Philosophy, European Society for Medical Oncology, Audit committee, Teaching hospital, Professor, Retirement, Journal, University Hospital (Newark, New Jersey), Ageing, Health, Ludwig Cancer Research, Annals of Oncology, Swiss, SIX Swiss Exchange, Teaching, International Association, Research, Attention, Annals, Security (finance), Editor-in-chief, Woman, Swiss Federal Institute of Technology, ESMO, Medicine, NSCLC, US, HKEX, Letter, Swiss Federal Institute of Aquatic Science and Technology, Part, University of Lausanne, Galenica, Strategic Advisory Board for Intellectual Property Policy, HK, Management, Nursing

The Board of HUTCHMED is of the view that Professor Peters will make significant contributions to the Company.

Key Points: 
  • The Board of HUTCHMED is of the view that Professor Peters will make significant contributions to the Company.
  • Mr Simon To, Chairman of HUTCHMED said “On behalf of the Board, I would like to extend a warm welcome to Professor Peters to the Company.
  • Professor Peters is also an independent director of Galenica AG, which is listed on the SIX Swiss Exchange.
  • The director’s fees of Professor Peters as an Independent Non-executive Director, member of the Technical Committee and member of the Audit Committee of the Company under her appointment letter are US$76,000, US$8,000 and US$13,500 per annum respectively.

Coffey Modica O'Meara LLP Names Karl MacGibbon Director of New Quality Assurance and Control Branch

Retrieved on: 
Monday, May 1, 2023
Control, Insurance, Specialty, Aviation, MGA, Swiss, CMO

WHITE PLAINS, N.Y., May 1, 2023 /PRNewswire/ -- Coffey Modica O'Meara LLP, a progressive, cutting-edge law firm focused on insurance defense, has created CMO Quality Assurance and Control, acronym CMOQAC.

Key Points: 
  • WHITE PLAINS, N.Y., May 1, 2023 /PRNewswire/ -- Coffey Modica O'Meara LLP, a progressive, cutting-edge law firm focused on insurance defense, has created CMO Quality Assurance and Control, acronym CMOQAC.
  • CMOQAC will help ensure compliance with client guidelines and assist with insurance company interaction and streamlining reports on processes.
  • CMOQAC will also support the training and gaining of an inside understanding of insurance companies and how to increase insurance IQ.
  • Karl MacGibbon has joined CMO as the Director of CMOQAC.

DIII-D National Fusion Facility Completes Highest-Powered Negative Triangularity Experiments in History of U.S. Fusion Research Program

Retrieved on: 
Monday, April 24, 2023
Columbia University, U.S. Department of Energy, Office of Inspector General, Swiss Federal Institute of Technology, Swiss, DIII-D, Field line, University, U.S. Department of Defense Strategy for Operating in Cyberspace, Electricity, Applied physics, Light, General Atomics, Columbia University Physics Department, Research, GA, Temperature, History, MIT, Associate, Plant, Plasma, Scientist, Student, United, Office of Science, School, Physics, Engineering education, Swiss Federal Institute of Aquatic Science and Technology, Massachusetts Institute of Technology School of Science, 1996-10-24 Frank Erwin Center, University of Texas, Austin, TX, Lithium, Management, Heating, ventilation, and air conditioning, Nursing, Science, Engineering

It produced the highest-powered negative triangularity experiments in the history of the U.S. fusion research program.

Key Points: 
  • It produced the highest-powered negative triangularity experiments in the history of the U.S. fusion research program.
  • DIII-D is an Office of Science scientific user facility, operated by General Atomics (GA) for the U.S. Department of Energy.
  • This is known as “positive triangularity” and is the configuration used in nearly every experiment at the DIII-D National Fusion Facility.
  • “The negative triangularity research team deserves a lot of credit for their planning and execution of this research campaign,” said Dr. Richard Buttery, Director of the DIII-D National Fusion Facility.

TAWANI Foundation Gifts Over $1.3M to the SETI Institute and the Field Museum in Honor of Earth Day

Retrieved on: 
Thursday, April 20, 2023
Field Museum of Natural History, Swiss, Swiss Federal Institute of Technology, Vrije Universiteit Brussel, Solar System, University, Prevalence, Life, SETI Institute, Exploration, Face, Ames Research Center, Geological Survey of India, Intelligence, Research, Pritzker family, History, Entomology, University of Innsbruck, SETI, Geology, Planet, RET, Knowledge, Cosmic dust, Environment, Swiss Federal Institute of Aquatic Science and Technology, Pharmaceutical industry, Rare-earth element, Silicon, Meteoritics

Chicago, April 20, 2023 (GLOBE NEWSWIRE) -- The TAWANI Foundation announces its commitment of $1.3M to the SETI Institute and continued support for the Robert A. Pritzker Center for Meteoritics and Polar Studies at the Field Museum in honor of Earth Day.

Key Points: 
  • Chicago, April 20, 2023 (GLOBE NEWSWIRE) -- The TAWANI Foundation announces its commitment of $1.3M to the SETI Institute and continued support for the Robert A. Pritzker Center for Meteoritics and Polar Studies at the Field Museum in honor of Earth Day.
  • This year, the Institute’s Anthropo Snow Project will receive $210,000, the first installment of a three-year gift totaling $630,000.
  • Heck serves as curator of Meteoritics and Polar Studies and senior director of research at the Field Museum.
  • “We are proud to support these and other paleoenvironmental studies this Earth Day and beyond.”
    To learn more about TAWANI Foundation grants, visit www.tawanifoundation.org/our-grants .